![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 29, 2019 2:50:41 PM
PSA;
Results: At entry, PA and PB pts were ~70 yrs with a Gleason score >8 and the majority had received prior abiraterone and/or enzalutamide. PB pts had higher median baseline (BL) PSA (40.6 vs. 20.8 ng/mL), and more prior enzalutamide (53 vs. 26%) and chemotherapy (49 vs. 36%) use vs PA pts. Overall, 2 PA (14%) v 16 PB pts (43%) had a decreased PSA post-BL. Of these, 7 PB (19%) vs. 0 PA pts achieved a confirmed PSA reduction ≥50% from BL. The median OS (months) in PB pts was 23 (17.4 -NR) vs. 8.5 (3.8-20.10) in PA pts. Median OS in PB pts with PSA reduction ≥50% from BL has not been reached as 100% (6/6) of pts are still alive. T cell reactivity, as measured by ELISpot assays, showed that 100% of PA (9/9) pts and 100% of PB (16/16) pts exhibited increases in the frequencies of T cells reactive to at least one prostate cancer antigen other than PSA, which is indicative of antigen spreading.
Conclusions: ADXS-PSA ± pembro elicited a broad antitumor T cell response in all mCRPC pts tested but only ADXS-PSA + pembro reduced PSA ≥50% from BL and prolonged OS in these select pts.
This is the part I like in relation to the PSA -“Median OS in PB pts with PSA reduction ≥50% from BL has not been reached as 100% (6/6) of pts are still alive.”
NEO:
Results. The turnaround time for manufacturing ADXS-NEO has consistently been ≤ 8 weeks from biopsy to first dose. Two pts treated at 1X109 CFU (dose level 1) experienced dose limiting toxicities (i.e., Gr 3 hypoxia ± Gr 3 hypotension) within 4 hours of completing the infusion of the second dose. These acute adverse events correlated with elevation of serum IL-6 and other cytokines, and both cases were manageable and reversible with tocilizumab and/or steroids. A dose de-escalation cohort was initiated at 1X108 CFU, which has been found to be safe and tolerated by one pt. In these pts, ADXS-NEO induced: 1) activation and proliferation of CD4+ / CD8+ T cells; 2) neoantigen-specific T cell responses after 1 week of the initial priming dose and 3) antigen spreading and T cell responses to neoantigens not selected by algorithm.
Conclusions. ADXS-NEO at 1X109 CFU was beyond the maximum tolerated dose but it was effective in eliciting a fast and broad anti-tumor immunity, including T cell responses to neoantigens and antigen spreading. Enrollment continues both in monotherapy and combination therapy arms with anti-PD-1/PD-L1 therapy,
Recent ADXS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:30:45 PM
- Form DEFM14C - Definitive information statement relating to merger or acquisition • Edgar (US Regulatory) • 03/05/2024 01:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:46 PM
- Form PREM14C - Preliminary information statements relating to merger or acquisition • Edgar (US Regulatory) • 02/20/2024 10:22:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:26:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 07:16:21 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:58:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 01:27:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:51:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/03/2024 09:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 02:04:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/21/2023 02:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 02:00:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:04:59 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 09:01:18 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:46:10 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:45:26 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 11:08:02 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/31/2023 11:05:10 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 10/23/2023 10:45:21 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM